Loading provider…
Loading provider…
Dermatology Physician in Tampa, FL
NPI: 1053630764Primary Employer
University Medical Service Association Inc
health.usf.edu
HQ Phone
Get MD Nishit's Phone Numberphone_androidMobile
Get MD Nishit's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
2013 - 2026

American Board of Dermatology
Dermatology

American Board of Preventive Medicine
Clinical Informatics
University of South Florida Morsani
Residency • Dermatology
2010 - 2014
USF Health Morsani College of Medicine
health.usf.edu
Medical School
Until 2010
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 256 | 393 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 222 | 317 |
| 3 | 17000Destruction of skin growth | 194 | 297 |
| 4 | 11102Tangential biopsy of single skin lesion | 193 | 253 |
| 5 | 17003Destruction of 2-14 skin growths | 155 | 823 |
Acquired acrodermatitis enteropathica as a presenting sign of celiac disease.
Authors: Rebecca Kissel, Lucia Seminario Vidal, Allison Weinkle
Journal: JAAD Case Rep
Publication Date: 2016-05-14
Advanced Management of Severe Keloids.
Authors: Christopher Nelson, Nicole Howe, Lisa Nyanda-Manalo, Thomas Hagele, George Cohen, Christopher Nelson
Journal: Skinmed
Publication Date: 2017-10-01
A comprehensive guide to the surgical management of nonmelanoma skin cancer
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: Ixekizumab
Lead Sponsor: Eli Lilly and Company
Collaborators: Incyte Corporation
Intervention / Treatment: DRUG: Baricitinib
Lead Sponsor: Eli Lilly and Company
Intervention / Treatment: DRUG: Placebo, DRUG: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3